Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Selvam R Sendhil"'
Autor:
Elizabeth Marrett, Winghan Jacqueline Kwong, Jipan Xie, Ameur M. Manceur, Selvam R. Sendhil, Eric Wu, Raluca Ionescu-Ittu, Janakiraman Subramanian
Publikováno v:
Drugs - Real World Outcomes, Vol 10, Iss 4, Pp 531-544 (2023)
Abstract Background Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR TKIs) are established first-line treatments among patients with metastatic non-small cell lung cancer harboring EGFR-sensitizing mutations. Upon EGFR TKI resistance
Externí odkaz:
https://doaj.org/article/9caad38b62b441cfafd81f36ac1d42c7
Autor:
David Singer, Philippe Thompson-Leduc, Siyu Ma, Deepshekhar Gupta, Wendy Y. Cheng, Selvam R. Sendhil, Manasvi Sundar, Ella Hagopian, Nikita Stempniewicz, Mei Sheng Duh, Sara Poston
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 11, Pp 2649-2668 (2023)
Abstract Introduction Patients with psoriasis (PsO) are at increased risk of herpes zoster (HZ), but recent data on the incidence of HZ among patients with PsO and the impact of HZ on healthcare resource use (HRU) and costs for patients with PsO have
Externí odkaz:
https://doaj.org/article/9ad5a8cee2e74c2898f82c08bc24f6ed
Autor:
Andreas Reiter, Jason Gotlib, Iván Álvarez-Twose, Deepti H. Radia, Johannes Lübke, Priyanka J. Bobbili, Aolin Wang, Chelsea Norregaard, Saša Dimitrijevic, Erin Sullivan, Melinda Louie-Gao, Juliana Schwaab, Ilene A. Galinsky, Cecelia Perkins, Wolfgang R. Sperr, Priya Sriskandarajah, Andi Chin, Selvam R. Sendhil, Mei Sheng Duh, Peter Valent, Daniel J. DeAngelo
Publikováno v:
Leukemia. 36:2108-2120
Advanced systemic mastocytosis (AdvSM) is a rare myeloid neoplasm associated with poor overall survival (OS). This study (NCT04695431) compared clinical outcomes between patients with AdvSM treated with avapritinib in the Phase 1 EXPLORER (NCT0256198
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::328e84008f695ad671d5dc3e26b468ea
https://doi.org/10.1038/s41375-022-01615-z
https://doi.org/10.1038/s41375-022-01615-z
Autor:
Daniel M, Geynisman, Ella X, Du, Xiaoran, Yang, Selvam R, Sendhil, Viviana Del, Tejo, Keith A, Betts, Stephen, Huo
Publikováno v:
Future Oncology. 18:1219-1234
Aims: To assess grade 3/4 adverse events (AEs) and costs of first-line nivolumab plus ipilimumab versus sunitinib in advanced or metastatic renal cell carcinoma. Methods: Individual patient data from the all treated population in the CheckMate 214 tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::266d5aea39b39f6ad03296da75117833
https://doi.org/10.2217/fon-2021-1109
https://doi.org/10.2217/fon-2021-1109
Autor:
Bradley McGregor, Daniel M Geynisman, Mauricio Burotto, Camillo Porta, Cristina Suarez, Maria T Bourlon, Viviana Del Tejo, Ella X Du, Xiaoran Yang, Selvam R Sendhil, Keith A Betts, Stephen Huo
Publikováno v:
Scientia
Background Despite 4 approved combination regimens in the first-line setting for advanced renal cell carcinoma (aRCC), adverse event (AE) costs data are lacking. Materials and Methods A descriptive analysis on 2 AE cost comparisons was conducted usin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24a1624d6b56737a87630493fac99671
https://hdl.handle.net/11351/9391
https://hdl.handle.net/11351/9391
Autor:
Courtney D Thornburg, Kelly Adamski, Keziah Cook, Mohini Vembusubramanian, Selvam R Sendhil, David Hinds, Er Chen, Joshua Sammon, Paul Solari, Louis P Garrison, Stacy E Croteau
Publikováno v:
Journal of managed carespecialty pharmacy. 28(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1ce4d74df67d3f4772a8ffc0897a170
https://pubmed.ncbi.nlm.nih.gov/34958235
https://pubmed.ncbi.nlm.nih.gov/34958235